Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed Low-dose vs Standard Heparin in VV-ECMO
NCT02966080Withdrawn
- Sponsor
- University of Arizona
- Start
- Dec 2016
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of heparin in thrombosis (2 arms), sponsored by University of Arizona. Primary endpoint: Significant bleeding complications. Planned start Dec 2016; status: withdrawn.
02
Drugs
heparin
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02966080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966080.